Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Genomics and risk stratification in high-risk prostate cancer

Nature Reviews Urology volume 16, pages 641–642 (2019)Cite this article

Subjects

Clinical and pathological risk grouping defines management in localized prostate cancer. Recent work suggests men with high-risk prostate cancer can be further subdivided into three risk groups (favourable high-risk, standard high-risk and very-high-risk) and that these groups correlate with measures of genomic risk, testing of which is increasingly being integrated into risk prediction.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The heterogeneity of high-risk prostate cancer.

References

  1. D’Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969–974 (1998).

    Article  Google Scholar 

  2. Mohler, J. L. et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 17, 479–505 (2019).

    Article  Google Scholar 

  3. Sundi, D. et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: validation study from 3 centers. Cancer 125, 391–397 (2019).

    Article  CAS  Google Scholar 

  4. Sanda, M. G. et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. part I: risk stratification, shared decision making, and care options. J. Urol. 199, 683–690 (2018).

    Article  Google Scholar 

  5. Muralidhar, V. et al. Definition and validation of “favorable high-risk prostate cancer”: implications for personalizing treatment of radiation-managed patients. Int. J. Radiat. Oncol. Biol. Phys. 93, 828–835 (2015).

    Article  Google Scholar 

  6. Muralidhar, V. et al. Genomic validation of 3-tiered clinical subclassification of high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2019.06.2510 (2019).

    Article  PubMed  Google Scholar 

  7. Stephenson, A. J. et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 23, 7005–7012 (2005).

    Article  Google Scholar 

  8. Cooperberg, M. R. et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur. Urol. 67, 326–333 (2015).

    Article  Google Scholar 

  9. Spratt, D. E. et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J. Clin. Oncol. 36, 581–590 (2018).

    Article  Google Scholar 

  10. Cooperberg, M. R. et al. The state of the science on prostate cancer biomarkers: the San Francisco consensus statement. Eur. Urol. https://doi.org/10.1016/j.eururo.2019.05.013 (2019).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

J.S. is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust and a Physician Scientist Training Award from the Damon Runyon Cancer Research Foundation.

Author information

Authors and Affiliations

  1. Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA

    Bashir Al Hussein Al Awamlh & Jonathan E. Shoag

Authors
  1. Bashir Al Hussein Al Awamlh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan E. Shoag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan E. Shoag.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

Decipher: https://decipherbio.com/

University of California San Francisco (UCSF)-Cancer of the Prostate Risk Assessment (CAPRA) score: https://urology.ucsf.edu/research/cancer/prostate-cancer-risk-assessment-and-the-ucsf-capra-score

Memorial Sloan Kettering Cancer Center’s prostate cancer nomograms: https://www.mskcc.org/nomograms/prostate/pre_op

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al Hussein Al Awamlh, B., Shoag, J.E. Genomics and risk stratification in high-risk prostate cancer. Nat Rev Urol 16, 641–642 (2019). https://doi.org/10.1038/s41585-019-0227-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0227-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing